- Home
- MTA vs AVIR Comparison
MTA vs AVIR Comparison
Compare MTA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- AVIR
- Stock Information
- Founded
- MTA 1983
- AVIR 2012
- Country
- MTA Canada
- AVIR United States
- Employees
- MTA N/A
- AVIR N/A
- Industry
- MTA
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- MTA
- AVIR Health Care
- Exchange
- MTA Nasdaq
- AVIR Nasdaq
- Market Cap
- MTA 267.2M
- AVIR 273.7M
- IPO Year
- MTA N/A
- AVIR 2020
- Fundamental
- Price
- MTA $2.92
- AVIR $3.01
- Analyst Decision
- MTA Hold
- AVIR Hold
- Analyst Count
- MTA 1
- AVIR 1
- Target Price
- MTA $4.50
- AVIR $6.88
- AVG Volume (30 Days)
- MTA 373.5K
- AVIR 263.3K
- Earning Date
- MTA 05-14-2025
- AVIR 03-06-2025
- Dividend Yield
- MTA N/A
- AVIR N/A
- EPS Growth
- MTA N/A
- AVIR N/A
- EPS
- MTA N/A
- AVIR N/A
- Revenue
- MTA $5,882,000.00
- AVIR N/A
- Revenue This Year
- MTA $37.69
- AVIR N/A
- Revenue Next Year
- MTA $120.61
- AVIR N/A
- P/E Ratio
- MTA N/A
- AVIR N/A
- Revenue Growth
- MTA 28.55
- AVIR N/A
- 52 Week Low
- MTA $2.32
- AVIR $2.75
- 52 Week High
- MTA $4.08
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- MTA 47.01
- AVIR 41.74
- Support Level
- MTA $2.95
- AVIR $2.90
- Resistance Level
- MTA $3.11
- AVIR $3.29
- Average True Range (ATR)
- MTA 0.13
- AVIR 0.12
- MACD
- MTA 0.00
- AVIR -0.01
- Stochastic Oscillator
- MTA 31.71
- AVIR 17.95
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).